The purpose of this study therefore is to determine whether CYP2C19 genotype-guided strategy for selection of clopidogrel in elderly patients aged over 75 years with ischemic stroke can reduces the occurrence of end events and better prevent stroke recurrence? This evidence concerns the gene CYP2C19 and ischemic stroke.